These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 23223539)

  • 1. Fingolimod treatment in multiple sclerosis leads to increased macular volume.
    Nolan R; Gelfand JM; Green AJ
    Neurology; 2013 Jan; 80(2):139-44. PubMed ID: 23223539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher macular volume in patients with MS receiving fingolimod: positive outcome or side effect?
    Dinkin M; Paul F
    Neurology; 2013 Jan; 80(2):128-9. PubMed ID: 23223537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis.
    Winges KM; Werner JS; Harvey DJ; Cello KE; Durbin MK; Balcer LJ; Calabresi PA; Keltner JL
    J Neuroophthalmol; 2013 Dec; 33(4):322-9. PubMed ID: 24051419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fingolimod therapy and macular hemorrhage.
    Bhatti MT; Freedman SM; Mahmoud TH
    J Neuroophthalmol; 2013 Dec; 33(4):370-2. PubMed ID: 23845997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
    Shmyrev VI; Kryzhanovskiĭ SM; Danilycheva IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):93-7. PubMed ID: 22677684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal quantitative assessment of macula during therapy with fingolimod in relapsing-remitting multiple sclerosis.
    Fruschelli M; Capozzoli M; Gelmi MC; Masi G; Annunziata P
    Int Ophthalmol; 2019 Apr; 39(4):777-781. PubMed ID: 29500696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macular oedema and changes in macular thickness in multiple sclerosis patients treated with fingolimod.
    Nørgaard TL; Andersen CU; Hilt C; Andersen CU
    Basic Clin Pharmacol Toxicol; 2020 Jun; 126(6):492-497. PubMed ID: 31880065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.
    Zarbin MA; Jampol LM; Jager RD; Reder AT; Francis G; Collins W; Tang D; Zhang X
    Ophthalmology; 2013 Jul; 120(7):1432-9. PubMed ID: 23531349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of fingolimod on B-cell populations in multiple sclerosis.
    Nakamura M; Matsuoka T; Chihara N; Miyake S; Sato W; Araki M; Okamoto T; Lin Y; Ogawa M; Murata M; Aranami T; Yamamura T
    Mult Scler; 2014 Sep; 20(10):1371-80. PubMed ID: 24526661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions.
    Mehling M; Kappos L; Derfuss T
    Curr Neurol Neurosci Rep; 2011 Oct; 11(5):492-7. PubMed ID: 21789537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fingolimod (FTY720) on cerebral blood flow, platelet function and macular thickness in healthy volunteers.
    Ocwieja M; Meiser K; David OJ; Valencia J; Wagner F; Schreiber SJ; Pleyer U; Ziemer S; Schmouder R
    Br J Clin Pharmacol; 2014 Dec; 78(6):1354-65. PubMed ID: 24976291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fingolimod is a potential novel therapy for multiple sclerosis.
    Aktas O; Küry P; Kieseier B; Hartung HP
    Nat Rev Neurol; 2010 Jul; 6(7):373-82. PubMed ID: 20551946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
    Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Famous.
    Kim MJ; Bhatti MT; Costello F
    Surv Ophthalmol; 2016; 61(4):512-9. PubMed ID: 26742785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
    Agashivala N; Wu N; Abouzaid S; Wu Y; Kim E; Boulanger L; Brandes DW
    BMC Neurol; 2013 Oct; 13():138. PubMed ID: 24093542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
    He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
    JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.
    Cohen M; Maillart E; Tourbah A; De Sèze J; Vukusic S; Brassat D; Anne O; Wiertlewski S; Camu W; Courtois S; Ruet A; Debouverie M; Le Page E; Casez O; Heinzlef O; Stankoff B; Bourre B; Castelnovo G; Rico A; Berger E; Camdessanche JP; Defer G; Clavelou P; Al Khedr A; Zephir H; Fromont A; Papeix C; Brochet B; Pelletier J; Lebrun C;
    JAMA Neurol; 2014 Apr; 71(4):436-41. PubMed ID: 24566807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Expert Opin Drug Saf; 2014 Jul; 13(7):989-98. PubMed ID: 24935480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the effect of fingolimod (FTY720) on macular perfusion by swept-source optical coherence tomography angiography in patients with multiple sclerosis.
    Karaküçük Y; Gümüş H; Eker S
    Cutan Ocul Toxicol; 2020 Sep; 39(3):281-286. PubMed ID: 32657164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation.
    Haghikia A; Gold R
    Am J Pathol; 2010 Jun; 176(6):2599-601. PubMed ID: 20395429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.